Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer

Explore whether FOLFOX6 as treatment could improve the TTP and OS of the patient with recurrent or metastatic esophagus

Inclusion criteria

• Histologically proven primary thoracic esophageal squamous cell carcinoma
• Without chemotherapy or neo-adjuvant chemotherapy in 6 weeks ,radiotherapy has end at least 1 month,target lesion was not in an irradiated area.
• Presence of at least one index lesion measurable by CT scan or MRI
• 18~75 years
• kps ≥ 70
• Life expectancy of ≥ 3 months
• ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L
• Cr ≤ 1.0×UNL
• TB ≤ 1.25×UNL； ALT/AST ≤ 2.5×UNL，THE patient with liver metastasis ALT/AST ≤ 5.0×UNL；AKP ≤ 2.5×UNL
• Signed written informed consent

Exclusion criteria

• Previous exposure to oxa therapy in one year
• diameter of tumor abdominal ≥ 10cm, Total volumes of liver lesions ≥ 50%,lung metastasis ≥ 25% total lung
• chronic diarrhea,enteritis,intestine obstruction which are not under control
• Psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol.
• peripheral neuropathy ≥ CTCAE 1
• Other serious disease
• Previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or endometrium treated five years prior to study entry.
• USE OTHER ANTITUMOR THERAPY
• Breast-feeding or pregnant women, no effective contraception if risk of conception exists